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Abstract. 
 
Male “viable motheaten” (
 
me
 
v
 
) mice, with a
naturally occurring mutation in the gene of the SH2 do-
main protein tyrosine phosphatase SHP-1, are sterile.
Known defects in sperm maturation in these mice cor-
relate with an impaired differentiation of the epididy-
mis, which has similarities to the phenotype of mice
with a targeted inactivation of the Ros receptor ty-
rosine kinase. Ros and SHP-1 are coexpressed in epi-
didymal epithelium, and elevated phosphorylation of
Ros in the epididymis of 
 
me
 
v
 
 mice suggests that Ros sig-
naling is under control of SHP-1 in vivo. Phosphory-
lated Ros strongly and directly associates with SHP-1 in
yeast two-hybrid, glutathione 
 
S
 
-transferase pull-down,
and coimmunoprecipitation experiments. Strong bind-
ing of SHP-1 to Ros is selective compared to six other
receptor tyrosine kinases. The interaction is mediated
by the SHP-1 NH
 
2
 
-terminal SH2 domain and Ros phos-
photyrosine 2267. Overexpression of SHP-1 results in
Ros dephosphorylation and effectively downregulates
Ros-dependent proliferation and transformation. We
propose that SHP-1 is an important downstream regu-
lator of Ros signaling.
Key words: protein tyrosine phosphatase • regulation
• receptor tyrosine kinase • epididymis • fertility
 
Introduction
 
The transmembrane tyrosine kinase Ros, encoded by the
 
protooncogene 
 
c-ros
 
, is an “orphan” receptor with exclu-
sive expression in specific epithelia (Sonnenberg et al.,
1991; Sonnenberg-Riethmacher et al., 1996). The first dis-
covered oncogenic variants of 
 
c-ros
 
 were found to encode
proteins with truncated extracellular domain, and they
were detected in a chick retrovirus and in human tumor
cell lines (Neckameyer and Wang, 1985; Birchmeier et al.,
1986). The oncogenic potential of the Ros tyrosine kinase
has also been demonstrated by ligand-dependent transfor-
mation of NIH3T3 fibroblasts, which were stably trans-
fected with a chimeric receptor consisting of the TrkA/
 
nerve growth factor (NGF)
 
1
 
 receptor extracellular domain
and the Ros transmembrane and cytoplasmic domains
(Riethmacher et al., 1994). The physiological function of
Ros has been characterized in mice with a targeted muta-
 
tion of 
 
c-ros
 
. Male Ros
 
2
 
/
 
2
 
 mice exhibit defects in differen-
tiation and regionalization of the epididymal epithelium
and, because of this defect, are sterile (Sonnenberg-Rieth-
macher et al., 1996).
The SH2 domain protein tyrosine phosphatase (PTP)
SHP-1 (Shen et al., 1991) is expressed in hematopoietic
and, at lower levels, epithelial cells. In the latter cell type,
SHP-1 expression is driven by a cell type–specific pro-
moter, which leads to the generation of an epithelial-spe-
cific SHP-1 variant (Banville et al., 1995). Multiple binding
partners and substrates for SHP-1 have been identified in
hematopoietic cells: SHP-1 negatively regulates the signal-
ing of cytokine receptors, receptor tyrosine kinases, adhe-
sion receptors, and immunoreceptors (for reviews see
Feng and Pawson, 1994; Frearson and Alexander, 1997;
Neel and Tonks, 1997). “Motheaten” (
 
me
 
) or “viable
 
motheaten” (
 
me
 
v
 
) mice carry mutations in the SHP-1 gene,
which lead to a complete loss or a 80–90% reduction of
SHP-1 activity, respectively (Green and Shultz, 1975;
Shultz et al., 1984, 1993). Homozygous 
 
me
 
 and 
 
me
 
v
 
 mice
exhibit multiple abnormalities, including immunodeficien-
cies, increased proliferation of macrophage, neutrophil,
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and erythrocyte progenitors (Shultz et al., 1997), and de-
creased bone density, which is a result of elevated osteo-
clast activity (Umeda et al., 1999). Cells isolated from 
 
me
 
and 
 
me
 
v
 
 mice allowed the identification of SHP-1 target
proteins in hematopoietic cells (Klingmüller et al., 1995;
Chen et al., 1996). In such cells, phosphorylation of the tar-
get proteins is elevated, either constitutively or upon acti-
vation of the appropriate signal transduction pathways.
Homozygous 
 
me
 
 mice die before they attain puberty. In
contrast, homozygous 
 
me
 
v
 
 mice reach a mean age of 8 to 9
wk, and male homozygous 
 
me
 
v
 
 mice are sterile. The de-
fects in 
 
me
 
v
 
/
 
me
 
v
 
 mice leading to sterility are incompletely
understood. A reduced testosterone level in these mice is
associated with impaired spermatogenesis. Interestingly,
testosterone treatment rescues spermatogenesis, but is not
sufficient to allow for the production of fully fertile sperm
(Shultz et al., 1984). This suggests that late stages of sperm
maturation in the epididymis are impaired in
 
 me
 
v
 
/
 
me
 
v
 
mice, as in Ros
 
2
 
/
 
2
 
 mice. The proximal segment of the epi-
didymis, where Ros and SHP-1 are coexpressed, is aber-
rantly differentiated in 
 
me
 
v
 
/
 
me
 
v
 
 mice. Therefore, we spec-
ulated that the defects in sperm maturation in Ros
 
2
 
/
 
2
 
 and
 
me
 
v
 
/
 
me
 
v
 
 mice might be related at the molecular level. If
Ros and SHP-1 interact in a common signal transduction
pathway, impairment of epididymal function might result
from inactivation of either gene. Indeed, our analysis re-
vealed that SHP-1 strongly binds Ros and regulates Ros
signaling in a negative manner. In 
 
me
 
v
 
/
 
me
 
v
 
 mice, Ros is hy-
perphosphorylated, consistent with an aberrant signaling
activity in vivo. We propose that Ros is a target of SHP-1
and that deregulated Ros activity in 
 
me
 
v
 
/
 
me
 
v
 
 mice contrib-
utes to male sterility.
 
Materials and Methods
 
Reagents, DNAs, and Mice
 
NGF
 
b
 
 was purchased from Biomol Feinchemikalien GmbH. Polyclonal
anti-phosphotyrosine and monoclonal anti–SHP-1 antibodies were ob-
tained from Transduction Laboratories, polyclonal anti–SHP-1 antibodies
and the corresponding blocking peptide from Santa Cruz Biotechnology,
Inc., and anti-vinculin monoclonal antibodies from Upstate Biotechnol-
ogy. Antibodies recognizing activated, phosphorylated extracellular signal
regulated kinases (Erks, “phospho-p44/42 MAPK antibody”) and against
Erk kinase (“pan-Erk antibody”) were from Cell Signaling Technology,
Inc., and Transduction Laboratories, respectively. The polyclonal anti-
Ros antibodies (directed against a COOH-terminal peptide of murine
Ros) have been described previously (Riethmacher et al., 1994). Human
SHP-1 cDNA was provided by Drs. A. Ullrich and R. Lammers (Max-
Planck-Institute für Biochemie, Martinsried, Germany), and cDNAs for
murine SHP-1 and human platelet-derived growth factor (PDGF)
 
b
 
 recep-
tor were obtained from Dr. M. Thomas (Washington University School of
Medicine, St. Louis, MO) and Drs. L. Claesson-Welsh and C.H. Heldin
(Ludwig Institute for Cancer Research, Uppsala, Sweden), respectively.
The chimerical TrkA-Ros (cloned in the eukaryotic expression vector
pEFBOS) has been described previously (Riethmacher et al., 1994; Sachs
et al., 1996). SHP-1 mutant 
 
me
 
v
 
 mice (C57aBL/6J-Hcph 
 
me
 
v 
 
[stock no.
000811], heterozygous breeding pairs and homozygous males) and control
animals (C57BL/6J) were purchased from the Jackson Laboratory. Geno-
typing was performed by PCR according to a protocol provided by the
Jackson Laboratory.
 
Expression of SHP-1 and Characterization of 
Epididymal Tissue
 
Expression analysis of SHP-1 in murine epididymis was carried out using
in situ hybridization. Labeled antisense riboprobe (corresponding to nu-
cleotides 164–1,349 in the murine SHP-1 cDNA; Matthews et al., 1992)
and a corresponding sense control, were prepared by in vitro transcription
 
in the presence of [
 
35
 
S]CTP and [
 
35
 
S]UTP using T7 and T3 RNA poly-
merases, respectively. In situ hybridization was carried out as described
previously (Sonnenberg et al., 1991). Expression of SHP-1 in human epi-
didymis was analyzed by immunohistochemistry. The anti–SH-PTP1 anti-
body C-19/sc-2872 (Santa Cruz Biotechnology, Inc.) was incubated with
5-
 
m
 
m tissue cryosections overnight at 4
 
8
 
C. After washing, the sections were
treated with a mouse anti–rabbit antibody (1:400; Dako), subsequently
with a rabbit anti–mouse immunoglobulin (1:70; Dako), and then with a
mouse APAAP (alkaline phosphatase monoclonal anti-alkaline phos-
phatase) complex (Dako). Naphtol-AS-biphosphate (Sigma-Aldrich) and
new fuchsin (Merck) were used as substrate and developer, respectively.
To inhibit endogenous tissue enzyme activity, the developing solution was
supplemented with 0.25 mM levamisole (Sigma-Aldrich). To evaluate the
specificity of immunostaining, the primary antibody was replaced by non-
immune serum, or the incubation was done in the presence of 100 
 
m
 
g/ml
of the corresponding blocking peptide.
To monitor tyrosyl phosphorylation in 
 
me
 
v
 
 mice, the animals were chal-
lenged with peroxovanadate (Ruff et al., 1997). For this, a pervanadate so-
lution was prepared by mixing a 5 mM solution of Na
 
3
 
VO
 
4
 
 with 30X H
 
2
 
O
 
2
 
to a final H
 
2
 
0
 
2
 
 concentration of 50 mM, and incubation was for 15 min at
room temperature. This solution was injected intraperitoneally (10 
 
m
 
l/g
body weight). After 10 min, the mice were killed; the epididymis, intes-
tine, and stomach were prepared and preserved either for histological ex-
amination or lysis. For lysis, the epididymis was shock frozen. The tissue
was lysed in lysis buffer (
 
z
 
 1 ml/2 glands) with the aid of a Dounce ho-
mogenizer. The lysates were centrifuged at 100,000 
 
g
 
 at 4
 
8
 
C for 30 min and
passed through a 0.22-
 
m
 
m filter. Lysate aliquots (
 
z
 
30 
 
m
 
g of total protein)
were used for SDS-PAGE and immunoblot analyses. Equal amounts of
lysates (500 
 
m
 
l, protein amounts equilibrated with lysis buffer) were used
for anti-Ros immunoprecipitations (10 
 
m
 
l anti-Ros antiserum/reaction).
Paraffin sections of murine epididymis were stained by hematoxylin/
eosin.
 
Expression Constructs
 
The TrkA-Ros chimera was recloned from pEFBOS to pcDNA3 using
EcoRI. Point mutations were introduced into the TrkA-Ros cDNA using
an M13 mutagenesis kit (Bio-Rad Laboratories), according to the manu-
facturer’s instructions. Mammalian expression constructs for SHP-1 and
various derivatives have been described previously (Tenev et al., 1997;
Keilhack et al., 1998), as were the bacterial glutathione 
 
S
 
-transferase
(GST)–fusion expression constructs of SHP-1, SHP-1 SH2 (tandem SH2
domains), SHP-1 R32K, SHP-1 R138K (Tenev et al., 1997), and SHP-1
 
D
 
41 (Frank et al., 1999). The construct for the production of a GST fusion
protein of the isolated NH
 
2
 
-terminal SH2 domain was generated by the di-
gestion of pGEX-5X-1 SH2 (see above) with EcoRI and SpeI. This frag-
ment was cloned into a modified pGEX-5X-1 vector (with an additional
XbaI site from pBKS) opened with EcoRI and XbaI. The COOH-termi-
nal SH2 domain was cloned by digestion of pGEX-5X-1 SH2 with SpeI
and SmaI. The fragment was treated with Pfu to create blunt ends and
cloned into pBKS, which was digested with SmaI. Subsequently the frag-
ment with the proper orientation was excised using EcoRI and NotI from
pBKS COOH-SH2 and ligated into pGEX-5X-1, which was opened with
EcoRI and NotI. SHP-1 CS was subcloned from pBKS to pGEX-5X-1 us-
ing EcoRI and NotI.
 
Yeast Two-Hybrid Assays
 
Constructs and the method for determining the interaction strength of a
panel of receptor tyrosine kinase cytoplasmic domains with various mole-
cules containing phosphotyrosine interaction domains were described ear-
lier (Weidner et al., 1996; Bai et al., 1998; Tamura et al., 1999; Vayssiere et
al., 2000). Interaction strength was assigned qualitatively by visual inspec-
tion of yeast growth in the appropriate selection medium compared to
other interaction partners as “strong,” “weak,” or “not detectable” (see
Fig. 4 A and Table I). For quantitative 
 
b
 
-galactosidase assays, cDNA frag-
ments representing the entire cytoplasmic domain of human PDGF
 
b
 
 re-
ceptor (Claesson-Welsh et al., 1988; amino acid [aa] 558–1,106) and mu-
rine c-Ros (Riethmacher et al., 1994; aa 1,880–2,339) were cloned into the
pLexA vector (CLONTECH Laboratories, Inc.). cDNA sequences corre-
sponding to the tandem SH2 domains and hinge domain of human SHP-1
(aa 1–270) or SHP-2 (aa 1–271) were cloned into pB42AD (CLONTECH
Laboratories, Inc.). Expression of all fusion proteins and autophosphory-
lation activity of kinase constructs were verified by immunoblotting. Ex-
pression constructs for the tested interaction partners were cotransformed
into 
 
Saccharomyces cereviseae
 
 strain EY48 (CLONTECH Laboratories,
Inc.), and individual colonies were spotted multiply on agar plates with
“induction medium” (synthetic dropout medium, Gal, Raf, 
 
2
 
His, 
 
2
 
Trp,
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2
 
Ura) containing X-gal (5-bromo-4-chloro-3-indolyl-
 
b
 
-
 
D
 
-galactopyrano-
side). Growth was allowed for several hours, then the plates were scanned
with a flat-bed scanner, and the mean intensity of color development was
determined by densitometric evaluation with the program NIH Image
1.57. Signals in the presence of both interaction partners were corrected
by subtraction of signals obtained with yeast transfected with expression
constructs for the kinase baits and empty pB42AD.
 
Transient Transfection, Immunoprecipitation, and 
Dephosphorylation Assay
 
293 cells were transfected with expression constructs for TrkA-Ros or
TrkA-Ros mutants, SHP-1, SHP-1 CS, or empty vector using calcium
phosphate coprecipitation (Lammers et al., 1993). For coimmunoprecipi-
tation, 10 
 
m
 
g pRK5RS SHP-1 or SHP-1 C455S DNA was cotransfected
with 10 
 
m
 
g pcDNA3 TrkA-Ros DNA per 10-cm dish. For assessment of
dephosphorylation, 0.5 
 
m
 
g pcDNA3 TrkA-Ros was cotransfected with 3.5
 
m
 
g pRK5RS SHP-1, pcDNA3 SHP-1 C455S, or empty vector in 6-well
plates. For titration of SHP-1 efficacy, variable amounts of pRK5RS SHP-1
were used (see the legend to Fig. 5 E). After transfection, the cells were
stimulated with 50 ng/ml NGF
 
b
 
 or vehicle for 10 min and lysed in 700 (10-
cm dish) or 200 
 
m
 
l (6-well plate) lysis buffer (20 mM Hepes, pH 7.4, 150
mM NaCl, 2 mM EDTA, 2 mM EGTA, 20 
 
m
 
M zinc acetate, 50 mM NaF,
10 mM NaPP, 1 mM Na
 
3
 
VO
 
4
 
, 1% Triton X-100, 1 mM PMSF, 1 
 
m
 
g/ml
pepstatin A, 2 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin). The lysates were clar-
ified by centrifugation at 25,000 
 
g
 
 and 4
 
8
 
C for 20 min. For coimmunopre-
cipitation, 10 
 
m
 
l anti-Ros antiserum or 1 
 
m
 
g monoclonal anti–SHP-1 anti-
body were used. Immunoprecipitation was carried out as described, and
associated proteins were analyzed by SDS-PAGE and immunoblotting.
For dephosphorylation assays, lysate aliquots were resolved by SDS-
PAGE, and the tyrosyl phosphorylation or activation of endogenous Erk
was visualized by immunoblotting.
 
GST Pull-down Assays and Sequential Immuno and 
Affinity Precipitations
 
For pull-down assays using different fusion proteins of SHP-1 domains, 20
 
m
 
g pcDNA3 TrkA-Ros was transfected into 293 cells (10-cm dishes). The
cells were stimulated with 50 ng/ml NGF
 
b
 
 for 10 min and lysed in 700 
 
m
 
l
lysis buffer. GST pull-down assays were done, as described previously
(Keilhack et al., 1998), using 20 pmol of each fusion protein. Sequential
immuno- and affinity precipitations to monitor direct phosphotyrosine-
mediated interactions were carried out as described previously (Keilhack
et al., 1998). In brief, 20 
 
m
 
g pcDNA3 TrkA-Ros or point mutants were
transfected into 293 cells (10-cm dishes). After transfection, the cells were
lysed and TrkA-Ros was immunoprecipitated. The immunoprecipitates
were denatured and partially renatured by dilution with lysis buffer.
These partially renatured lysates were applied to 2 
 
m
 
g GST-SH2 immobi-
lized on glutathione-Sepharose (Amersham Pharmacia Biotech). Bound
proteins were visualized by SDS-PAGE and immunoblotting.
 
Establishment of Inducible SHP-1–expressing NIH3T3 
TrkA-Ros Cells
 
NIH3T3 cells stably transfected with TrkA-Ros (using G418 resistance for
selection) (Riethmacher et al., 1994) were supertransfected with SHP-1
DNA in the tetracycline-regulated expression vector pNRTIS-21 (pNR-
TIS SHP-1) (Tenev et al., 2000) and pSBC (with a hygromycin resistance
gene) (Tenev et al., 2000) in a 5:1 ratio in 24-well plates using Superfect
(QIAGEN), according to the manufacturer’s instructions. The cells were
selected with 100 ng/ml anhydrotetracycline (ATc), 200 
 
m
 
g/ml hygromycin
B, and 400 
 
m
 
g/ml G418 until colonies formed. The cells were then ampli-
fied and clones were generated using limited dilution. Clones that induc-
ibly expressed SHP-1 upon ATc withdrawal were selected for further
analysis. Tyrosyl phosphorylation of TrkA-Ros in these cell clones was
tested after the cells were grown for 5 d in the absence or presence of 100
ng/ml ATc (six-well plates). Thereafter, cells were treated with 100 or 200
ng/ml NGF
 
b
 
 or vehicle and lysed in 200 
 
m
 
l lysis buffer. TrkA-Ros was im-
munoprecipitated and its tyrosyl phosphorylation was assessed using SDS-
PAGE and immunoblotting. To monitor growth, the cell clones were
grown with or without 100 ng/ml ATc for 5 d. Thereafter, 5 
 
3 
 
10
 
4 
 
cells
were seeded into six-well plates and kept for 8 d with or without 100 ng/ml
ATc and in the absence or presence of 50 ng/ml NGF
 
b
 
. The medium was
changed every second day. Subsequently, the cells were trypsinized and
counted. The results are represented as fold growth and compared to the
seeded number of cells. For focus assays, cell monolayers were grown in
the absence or presence of 50 ng/ml NGF
 
b
 
 for 12 d (the medium was
changed every second day). Subsequently, the monolayers were stained
with crystal violet dye and photographed. Alternatively, a small number
of transfected cells were tested for their ability to form foci in a monolayer
of wild-type NIH3T3 fibroblasts. 20 transfected cells were mixed with 10
 
6
 
wild-type cells and seeded in 6-cm dishes. The cells were kept for 14 d with
or without 100 ng/ml ATc in the absence or presence of 50 ng/ml NGF
 
b
 
(the medium was changed every second day), and foci were counted after
staining the plates.
Figure 1. Epididymal differentiation is impaired in homozygous
mev mice. Paraffin sections of the epididymis of heterozygous,
mev/mev, and Ros2/2 mice were stained with hematoxylin/eosin.
Depicted sections represent the proximal segment of the epididy-
mal caput at a magnification of 643. Bars, 30 mm.
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Figure 2. SHP-1 is expressed in the epididymal epithelium. A–E show the expression of SHP-1 mRNA in murine epididymis (wild-type ani-
mals) by in situ hybridization. (A) Overview in dark-field representation (antisense riboprobe). Bar, 1 mm. (B) SHP-1 mRNA expression in
the proximal tubules at higher magnification. (C) Sense riboprobe control. (D and E) Sections from B and C, respectively, shown in differen-
tial interference contrast. Bar, 200 mm. (F) Expression of SHP-1 in human epididymis by immunocytochemistry with anti–SHP-1 antibodies.
(G) Negative control for F. The incubation with the primary antibody was performed in the presence of excess antigenic peptide. Bar, 50 mm.
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Results
Ros Is Hyperphosphorylated in the Epididymis of
mev Mice
To assess whether SHP-1 might be relevant for epididy-
mal function, we histologically examined the epididymis of
male mev/mev mice and compared them to heterozygous con-
trols. Macroscopically, the epididymis of mev/mev mice was
smaller, though the overall shape appeared normal. This
size reduction was proportional to the reduced body weight
of the mev/mev mice. Histological sections revealed that the
tall columnar epithelial cells, which form the tubules of the
proximal segment in heterozygous animals, are replaced by
considerably flatter epithelial cells in the epithelium of mev/
mev mice (Fig. 1). In heterozygous animals, these epithelial
cells are clearly structured. The nucleus is located above a
clearly defined basal cytoplasmic zone. The cytoplasmic
zone above the nucleus is broad and the apical surface is
rough. In contrast, the nuclei in epithelial cells of mev/mev
are often located closer to the basal membrane, and the api-
cal surfaces appear smooth (Fig. 1). The epithelium in the
more distal segments of the epididymis exhibited little dif-
ferences in mutant and control animals (not shown). Histo-
logically, the epithelium of the proximal segment in mev/mev
mice has similarities to that of Ros2/2 mice (Fig. 1). We also
analyzed the epithelium of other organs. Epithelial cells in
the intestine of mev/mev mice were smaller than their coun-
terparts in heterozygous animals, but appeared fully differ-
entiated. No differences between mev/mev and heterozygous
animals were detectable in epithelia of stomach and pan-
creas (not shown). In summary, the epididymal epithelium
of mev/mev mice exhibits signs of aberrant differentiation.
This phenotype may be related to a loss of function of SHP-1
in the epididymal epithelial cells, since SHP-1 is clearly ex-
pressed in these cells (Fig. 2). In situ hybridization with an
antisense RNA generated from a 1,184-bp fragment of mu-
rine SHP-1 cDNA revealed expression of SHP-1 mRNA in
the epithelial cells surrounding the tubules of the initial epi-
didymal segment (Fig. 2, A–E). More distal segments ex-
hibit low level signals. Thus, SHP-1 expression mirrors the
one of Ros in this part of the epididymis (Sonnenberg-
Riethmacher et al., 1996). Strong SHP-1 expression is also
seen in the corpus with highest levels in the most distal seg-
ments. These distal epithelia are devoid of Ros (Sonnen-
berg-Riethmacher et al., 1996). SHP-1 expression could also
be detected by immunoblotting in the epididymis of mice
(not shown); immunostaining failed with the available anti-
bodies. However, in human epididymis, strong epithelial
SHP-1 expression could be visualized by immunohisto-
chemistry (Fig. 2, F and G). Thus, SHP-1 is expressed in ep-
ithelial cells of the epididymis and exhibits an overlapping
expression domain with Ros.
The overlapping expression of SHP-1 and Ros prompted
us to test whether impairment of SHP-1 activity in mev/mev
mice might affect Ros signaling. We analyzed tyrosine phos-
phorylation of immunoprecipitated Ros from the epididy-
mis of mev/mev mice. Ros from mev/mev mice displayed an
elevated tyrosine phosphorylation compared to Ros from
heterozygous animals (Fig. 3), indicating that SHP-1 is ca-
pable of downregulating Ros signaling in the epithelium of
the epididymis in vivo. Intraperitoneal injection of peroxo-
vanadate rapidly triggers tyrosine phosphorylation in multi-
ple murine tissues (Ruff et al., 1997). After treatment with
peroxovanadate, a dramatic increase in overall tyrosyl
phosphorylation was detected in epididymal extracts from
mev/mev mice, which was less pronounced in heterozygous
mice (Fig. 3). In particular, phosphorylation of Ros was
strongly elevated in peroxovanadate-treated homozygous,
but not in heterozygous mev mice. Peroxovanadate is an ef-
fective inhibitor of many PTPs, but a relatively weak inhibi-
tor of SHP-1 (Wetzker, M., and F.D. Böhmer, unpublished
data). We assume that partial inhibition of SHP-1 by the
pervanadate treatment eliminates the residual activity of
SHP-1 in the mev/mev mice, but leaves substantial activity in
the heterozygous mice intact, resulting in a further enhance-
ment of the difference in Ros phosphorylation level.
Ros and SHP-1 Exhibit a Strong and Direct Interaction
To further investigate the regulation of Ros by SHP-1, we
tested whether SHP-1 is a direct binding partner for Ros in
a yeast two-hybrid assay. The cytoplasmic domain of Ros
was fused to the DNA-binding domain of LexA. In such
constructs, the tyrosine kinase of the fusion proteins is
constitutively active, phosphorylated, and can interact
with cognate binding partners (Weidner et al., 1996). We
observed very strong binding between the SH2 domains of
SHP-1 and the cytoplasmic domain of Ros (Table I).
Figure 3. SHP-1 affects Ros signaling in vivo. mev/mev mice or
heterozygous control animals were challenged with peroxovana-
date (POV) or mock treated (2). The epididymis was prepared
and the tissue was lysed. Lysates were used to analyze the phos-
photyrosine content (left gel, anti-PY) by immunoblotting. In ad-
dition, lysates were used for immunoprecipitation (IP) of Ros
and for the subsequent analysis of Ros phosphorylation, by im-
munoblotting (right gel). The data are representative of three in-
dependent experiments with consistent results.
Table I. Interaction of Various Autophosphorylated Receptor 
Tyrosine Kinases with SHP-1 and Other Signaling Proteins in 
Yeast Two-Hybrid Assays
RTK (cytoplasmic domain
fusion protein as bait)
Binding strength
of SHP-1 SH2 domains*
Strongly binding
signaling molecules
Ros Strong PLCg, c-Abl SH2
TrkA§ Not detectable PLCg
Insulin receptor Not detectable p85a
IGF-1 receptor§ Not detectable p85a
CSF-1 receptor§ Not detectable Grb2, Grb10
Met/HGF receptor§ Weak Gab1, Grb2
*The interactions were tested in yeast colony growth assays as shown in Fig. 4 A. See
text for further description of the signaling proteins. 
§TrkA, NGF receptor; IGF-1, insulin-like growth factor-1; CSF-1, colony-stimulating
factor-1; HGF, hepatocyte growth factor.
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Other tested receptor tyrosine kinases (RTKs) exhibited
little or no detectable interaction with SHP-1 SH2 do-
mains, but interacted strongly with other partners. Thus,
the direct binding of SHP-1 to Ros is remarkably specific
compared to other tested receptor baits. In addition to the
SH2 domains of SHP-1, phospholipase Cg, the SH2 do-
main of c-Abl, the phosphoinositide-3 kinase subunit
p85a, Grb10, and the SH2 domains of SHP-2 were strong
binding partners for Ros, whereas the signaling adapter
proteins Shc, Grb7, Crk, and Nck bound to a lesser extent.
The adapter protein Grb2, the Gab1 Met-binding domain,
GTPase-activating protein, and the phosphoinositide-3 ki-
nase subunit p55 exhibited no detectable binding (Fig. 4
A, and data not shown). Interestingly, full-length SHP-1
did not interact with Ros in this assay, suggesting that the
presence of the catalytic domain of the PTP prevents the
formation of a stable complex. Strong interaction of SHP-1
SH2 domains with Ros was confirmed using an alterna-
tive yeast two-hybrid assay that allows quantification (Fig.
4 B). Only a weak interaction of the SHP-1 SH2 domains
was detectable with the PDGFb-receptor cytoplasmic do-
main. For comparison, the SH2 domains of SHP-2 were
tested, since binding of SHP-2 to the PDGFb receptor has
been established (Valius et al., 1993). They bound with
comparable strength to PDGFb receptor and Ros baits.
We further tested the interaction between SHP-1 and
Ros in mammalian cells, using transient transfections of
HEK293 cells. Since the ligand for Ros is unknown, we
used a chimerical receptor composed of the extracellular
part of human TrkA and the intracellular domain of mu-
rine Ros (TrkA-Ros), which is activated in response to
NGFb (Riethmacher et al., 1994). The chimerical receptor
was expressed, alone or together, with wild-type SHP-1 or
with a catalytically inactive SHP-1 mutant (C455S). Immu-
noprecipitations demonstrate the formation of a complex
between active SHP-1 and TrkA-Ros in NGFb-stimu-
lated, but not -unstimulated, cells (Fig. 5 A). Moreover, a
very strong complex formation occurred between the
C455S mutant of SHP-1 and TrkA-Ros, even without
ligand addition, which was further enhanced by NGFb
stimulation. Thus, SHP-1 binds Ros also in mammalian
cells; catalytic activity of SHP-1 reduces binding, as ob-
served in the yeast two-hybrid system. In addition, “sub-
strate trapping” of SHP-1 C455S may contribute to the
very efficient association with Ros. The strong binding of
SHP-1 C455S in the absence of NGFb is likely due to sig-
nificant constitutive activity of TrkA-Ros tyrosine kinase
caused by overexpression.
SHP-1 Binds to Ros Phosphotyrosine 2267 via the
NH2-terminal SH2 Domain
To identify the domains of SHP-1 that are necessary for the
interaction with TrkA-Ros, we used GST pull-down assays
with HEK293 lysates containing autophosphorylated TrkA-
Ros (Fig. 5 B). The lysates were incubated with equal molar
amounts of GST, GST fusion proteins that contain full-
length SHP-1, and various SHP-1 derivatives. The amount
of TrkA-Ros recovered on GSH beads was analyzed by im-
munoblotting (Fig. 5 B). In such an assay, TrkA-Ros can be
precipitated with fusion proteins that contain an intact NH2-
terminal SH2 domain of SHP-1. Very little if any binding
was observed to the other SHP-1 subdomains, for instance
the isolated COOH-terminal SH2 domain. Thus, the NH2-
terminal SH2 domain plays a dominant role in the interac-
tion with Ros. Guided by the consensus sequence for
ligands of the NH2-terminal SH2 domains of SHP-1,
hXY(P)XXh (X 5 any amino acid and h 5 hydrophobic
Figure 4. The SHP-1 SH2 domains are strong binding partners
for Ros in yeast two-hybrid assays. (A) The interaction of various
signaling molecules as “prey” (indicated) with the autophos-
phorylated cytoplasmic domain of Ros as “bait” was tested in
yeast colony growth assays. (B) The interaction of the SH2 do-
mains of either SHP-1 or the related PTP SHP-2 with Ros or, for
comparison, with the PDGFb receptor was quantitatively mea-
sured with a b-galactosidase reporter gene assay. Colonies were
spotted on X-gal–containing plates and color development, as de-
picted in the top picture, were quantitated by densitometry
(graph, mean 6 SD, n 5 6).
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amino acids) (Burshtyn et al., 1997), we identified various
putative tyrosine residues as potential SHP-1–binding sites.
These tyrosine residues in TrkA-Ros were mutated to phe-
nylalanine and the obtained TrkA-Ros mutants were com-
pared to wild-type TrkA-Ros for their ability to interact di-
rectly with the SH2 domains of SHP-1. For this, a previously
described sequential immuno- and affinity precipitation as-
say (Keilhack et al., 1998) was employed, which permits
only detection of direct interactions, but not binding medi-
ated via adapter proteins. The mutation Y2267F interfered
with the interaction of the SHP-1 SH2 domain; the Y2166F
and Y2327F mutations had little effect (Fig. 5 C). Thus,
phosphotyrosine 2267 in the Ros sequence is the major di-
rect binding site for the SH2 domains of SHP-1.
SHP-1 Dephosphorylates Ros and Inhibits
Ros-dependent Cell Growth and Transformation
To assess whether the Ros-SHP-1 interaction results in
SHP-1–mediated Ros dephosphorylation, we coexpressed
TrkA-Ros with SHP-1 or with the catalytically inactive
SHP-1 C455S mutant in HEK293 cells. The cells were
stimulated with NGFb, and the phosphotyrosine content
was analyzed by immunoblotting (Fig. 5 D). TrkA-Ros
overexpression led to a massive tyrosine phosphorylation
Figure 5. SHP-1 interacts with and dephosphorylates autophosphorylated TrkA-Ros. (A) SHP-1
wild-type (WT) or a catalytically inactive SHP-1 mutant (CS) were coexpressed with TrkA-Ros in
HEK293 cells, and the cells were stimulated with NGFb or vehicle. Cell lysates were used for re-
ciprocal coimmunoprecipitation experiments. (B) HEK293 cell lysates containing autophosphory-
lated TrkA-Ros were used in GST pull-down assays using different fragments of SHP-1 as GST fu-
sion proteins. CAT, catalytic domain; SH2, SH2 domains; NSH2, isolated NH2-terminal SH2
domain; CSH2, isolated COOH-terminal SH2 domain; SHP-1, full-length enzyme; SHP-1 D41, 41
amino acids deleted at the COOH-terminus; SHP-1 R32K, inactivated NH2-terminal SH2 domain;
SHP-1 R138K, inactivated COOH-terminal SH2 domain. (C) Denatured and partially renatured
anti-Ros immunoprecipitates containing wild-type TrkA-Ros or point mutants were used in GST
pull-down assays using the isolated SH2 domains of SHP-1 as a GST fusion protein or GST alone
(sequential immuno- and affinity precipitation). Expression controls for the different TrkA-Ros
variants are shown in the bottom gel. (D) SHP-1 WT and SHP-1 C455S were coexpressed with
TrkA-Ros in HEK293 cells, and the cells were stimulated with NGFb. Lysate aliquots were used to
analyze the phosphotyrosine content by SDS-PAGE and immunoblotting. (E) Effect of different
amounts of SHP-1 on Ros-dependent tyrosine phosphorylation and Erk activation. TrkA-Ros
(wild-type) and TrkA-Ros Y2267F were coexpressed with different amounts of SHP-1 (expression
plasmid amounts indicated). Total cell lysates were evaluated for tyrosine phosphorylation and ac-
tivity of endogenous Erk by immunoblotting with anti-phosphotyrosine (anti-PY) and anti–phos-
pho-Erk (pErk) antibodies. Quantification of Ros tyrosine phosphorylation and phospho-Erk sig-
nals is depicted in the graph. Consistent results were obtained in three independent experiments.
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of TrkA-Ros and other proteins. The C455S mutant of
SHP-1 had virtually no effect, whereas SHP-1 expression
resulted in a complete disappearance of the phosphory-
lated proteins. We reproducibly observed some reduction
of the TrkA-Ros protein level upon SHP-1 transfection;
this decrease in expression may contribute, but is by far
not sufficient to explain the reduced phosphorylation level
of TrkA-Ros. Thus, a very pronounced suppression of
Ros-dependent tyrosine phosphorylation is mediated by
the catalytic activity of SHP-1. This effect could be ac-
counted for by a direct dephosphorylation of TrkA-Ros
and, subsequently, a decrease of its kinase activity and
substrate binding and/or by the dephosphorylation of
TrkA-Ros substrates.
We compared the relative susceptibility of TrkA-Ros
signaling activity with that of the TrkA-Ros Y2267F mu-
tant. The Y2267F mutant exhibited a reduced autophos-
phorylation and phosphorylation of cellular substrates,
presumably resulting from loss of a major autophosphory-
lation site (Fig. 5 E). However, the level of activation of
Erk was similar in cells expressing either TrkA-Ros vari-
ant. Consistent with the loss of direct SHP-1 binding,
phosphorylation activity of the TrkA-Ros Y2267F mutant
and TrkA-Ros Y2267F-dependent Erk phosphorylation
were less effectively downregulated by SHP-1 than in the
case of wild-type TrkA-Ros. This finding supports the
functional importance of direct SHP-1 binding to Ros for
negative regulation of signaling activity. Still, signaling of
TrkA-Ros Y2267F is negatively affected by SHP-1, in par-
ticular, at higher SHP-1 levels (Fig. 5 E), suggesting the
additional operation of an indirect Ros-SHP-1 interaction
in intact cells.
Proliferation of stably TrkA-Ros–expressing NIH3T3 fi-
broblasts can be stimulated with NGFb; upon prolonged
NGFb stimulation, the cells assume a transformed phe-
notype (Riethmacher et al., 1994). We established de-
rivatives of TrkA-Ros–expressing NIH3T3 cells, which
express SHP-1 in a tetracycline-regulated manner. Cell
clones containing the inducible SHP-1 expression vector
were isolated and tested for the effect of SHP-1 on the
TrkA-Ros phosphorylation. To induce or suppress SHP-1
expression, cells were cultured in the absence or presence
of ATc. After stimulation with different NGFb concentra-
tions (Fig. 6 A), phosphorylation of TrkA-Ros was moni-
tored. SHP-1 expression led to a reduction of the NGFb-
stimulated tyrosine phosphorylation of TrkA-Ros. Thus,
as in HEK293 cells, TrkA-Ros is an efficient substrate for
SHP-1 in NIH3T3 cells.
Figure 6. SHP-1 inhibits Ros-dependent cell growth and transformation. (A) NIH3T3
fibroblasts, stably transfected with TrkA-Ros, were supertransfected with SHP-1 using
a tetracycline-inducible expression system (Tet-off system). Cells cultured in the ab-
sence or presence of ATc were stimulated with different concentrations of NGFb.
TrkA-Ros was immunoprecipitated and the tyrosine phosphorylation was monitored
by immunoblotting. (B) The growth of the cells in the absence or presence of ATc and in the absence or presence of NGFb was ana-
lyzed. The results are represented as fold growth after 8 d and compared to the seeded number of cells (mean of triplicates). (C) To an-
alyze focus formation, cell monolayers were grown in the absence or presence of ATc and in the absence or presence of NGFb for 12 d.
Then, the monolayers were stained with crystal violet dye. In an alternative type of assay, we tested focus formation in the presence of
an excess of parental NIH3T3 cells. When 20 transfected cells were mixed with 106 parental cells, the following numbers of foci per dish
were observed in a typical experiment: 1ATc, 1NGFb: 9; 1ATc, 2NGFb: 2; 2ATc, 2NGFb: 0; and 2ATc, 1 NGFb: 0.
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We further assessed whether the SHP-1–mediated de-
crease of TrkA-Ros phosphorylation changes the growth
behavior of the NIH3T3 fibroblasts. SHP-1 expression was
induced (2ATc) or suppressed (1ATc) in cells grown in
the absence or presence of NGFb in low serum. NGFb
treatment resulted in a stimulation of cell proliferation
(Fig. 6 B). Expression of SHP-1 attenuated growth of the
cells in the absence of NGFb, and strongly compromised
the growth stimulation by NGFb. Thus, SHP-1 negatively
regulates the TrkA-Ros–mediated growth response. When
cultured with NGFb and in the presence of ATc (suppres-
sion of SHP-1 expression), the cells spontaneously formed
multiple foci (Fig. 6 C). Induction of SHP-1 expression in
NGFb-treated cells completely suppressed focus forma-
tion. No foci were formed in the absence of NGFb, regard-
less of whether the cells did or did not express SHP-1.
Likewise, the ability of a small number of transfected cells
to form foci in a monolayer of untransfected NIH3T3 fi-
broblasts (Riethmacher et al., 1994) was suppressed by
SHP-1 expression, as explained in the legend to Fig. 6. In
summary, SHP-1 can suppress Ros-dependent phosphory-
lation, cell proliferation, and transformation.
Discussion
The signal transduction of receptor tyrosine kinases is
modulated by PTPs, however, the identity of relevant PTP
molecules is often not known. For the SH2 domain PTP
SHP-1, a negative regulator of signal transduction, various
targets in hematopoietic cells have been identified, includ-
ing the RTK Kit/SCF receptor (Lorenz et al., 1996; Paul-
son et al., 1996) and the CSF-1 receptor (Chen et al.,
1996). Here, we present evidence for an epithelial target of
SHP-1: the “orphan” RTK Ros. We show that SHP-1 and
Ros are coexpressed in the proximal segment of the epi-
didymal caput. In agreement with a functional interaction
of Ros and SHP-1 in these cells, we observed hyperphos-
phorylation of Ros in mev mice, whose SHP-1 activity is
strongly compromised. Experiments in different cellular
models further support that SHP-1 is an effective negative
regulator of Ros phosphorylation and signaling.
The effects of SHP-1 appear to be mediated by a re-
markably efficient and direct binding to the phosphory-
lated Ros receptor. Direct binding is mediated by the
NH2-terminal SH2 domain of SHP-1 and phosphotyrosine
2267 in the COOH-terminal part of Ros. The Ros se-
quence LNY2267MVL matches the known consensus for
binding the SHP-1 NH2-terminal SH2 domain and may
mediate a particularly high affinity interaction. Alterna-
tively, a very high stoichiometry of phosphorylation of this
site may explain the high efficiency of interaction. Phos-
phorylated Ros is not only a strong binding partner for
SHP-1, but also a very good substrate. Dephosphorylation
of Ros appears to include the tyrosine that serves as a
binding site of the SHP-1 SH2 domain, which abolishes
binding. This would explain why no interaction is observed
between Ros and a catalytically active SHP-1 protein in
yeast two-hybrid interaction experiments, though Ros and
the SH2 domain of SHP-1 interact strongly. Similarly, the
amounts of detectable SHP-1–TrkA-Ros complex are
highly elevated when a catalytically inactive variant of
SHP-1 is used in coimmunoprecipitation and pull-down
experiments. Destruction of a SHP-1–binding site by SHP-
1–mediated dephosphorylation has been previously ob-
served for the interleukin 3 receptor (Bone et al., 1997).
Coexpression of SHP-1 with the TrkA-Ros chimera leads
not only to dephosphorylation of TrkA-Ros, but also abol-
ishes tyrosine phosphorylation of other substrates. This
could be correlated to dephosphorylation of Ros, which
will lead to a decrease of the catalytic activity of its kinase
and a decrease of the capacity to recruit substrate proteins.
Alternatively, or in addition, Ros substrates may also be-
come directly dephosphorylated by SHP-1.
The hitherto best understood function of Ros is its role
in differentiation and regionalization of the epididymal
epithelium of mice; the correct development of this epithe-
lium is essential for male fertility. Deregulation of epididy-
mal differentiation in Ros2/2 mice leads to sterility (Son-
nenberg-Riethmacher et al., 1996). Sterility is due to
subtle defects in sperm maturation, which have not yet
been characterized at the molecular level (Cooper, 1998;
Yeung et al., 1998). It is possible that the phenotypic ab-
normalities that we have observed in the epididymis of
male mev/mev mice contribute to the sterility of these mice
in a similar manner. We observed histological aberrations
only in the most proximal segment of the epididymis, i.e.,
in the region where SHP-1 and Ros are coexpressed. Our
results for the SHP-1/Ros interaction in vitro and the ob-
servation that Ros is hyperphosphorylated in mev/mev
mice in vivo strongly suggest an elevated level of Ros sig-
naling activity in these animals. It is possible that the histo-
logical changes in the caput epididymis of mev/mev mice
are the consequence of deregulated Ros activity. It is obvi-
ous that the molecular consequences of Ros inactivation
and elevated Ros signaling in epididymal cells will be very
different. Interestingly, the phenotypic abnormalities seen
in the epididymis of Ros2/2 mice and mev/mev mice have
similarities on the morphological level. A more detailed
characterization of the functional defects in epididymal
differentiation in mev/mev, as well as Ros2/2, mice will be
required to better define similarities and differences of the
two phenotypes.
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